{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-17T01:31:27.801165+00:00","published_at":"2026-10-16T13:52:50.363049+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:w44ar3ftq8vd","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-03-26","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:chris-cabell-m-d","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:14"],"evidence_ids":["alpha:projection-evidence:document:4677cf46d4312514a369c9980988ca1b826ef2c79f258338999aeefa62c8ce3f"],"summary":"Chris Cabell, M.D. executive of Inhibikase Therapeutics, Inc., effective 2026-03-26.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1m9zk9b14qfty5","event_type":"CFO_CHANGED","effective_at":"2026-03-26","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:david-mcintyre","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:15"],"evidence_ids":["alpha:projection-evidence:document:267fc6e9478bfc77e8e15176a516a660226d070498ea965a58148cae2381f6c9"],"summary":"David McIntyre executive of Inhibikase Therapeutics, Inc., effective 2026-03-26.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:xmfw6c19qw3nq","event_type":"CEO_CHANGED","effective_at":"2026-03-26","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:mark-iwicki","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:16"],"evidence_ids":["alpha:projection-evidence:document:cee5c39c7287118d2ff6c66487225b929867ec0e421959c8e49a65ce773c4dff"],"summary":"Mark Iwicki executive of Inhibikase Therapeutics, Inc., effective 2026-03-26.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1gxqxaw1cwrr8e","event_type":"DIRECTOR_APPOINTED","effective_at":"2025-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:mark-iwicki","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Mark Iwicki seat on Inhibikase Therapeutics, Inc., effective 2025-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:xu5yvn1rftizp","event_type":"DIRECTOR_APPOINTED","effective_at":"2025-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:vincent-aurentz","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:13"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Vincent Aurentz seat on Inhibikase Therapeutics, Inc., effective 2025-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:5bc14klg7xcq","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2025-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:vincent-aurentz","alpha:committee:inhibikase-therapeutics-inc:nominating-and-governance"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:24"],"evidence_ids":["alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949"],"summary":"Vincent Aurentz member of Nominating and Governance, effective 2025-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:zoxstl14w5q3v","event_type":"DIRECTOR_APPOINTED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:amit-munshi","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Amit Munshi seat on Inhibikase Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:cvzup41ri85ws","event_type":"DIRECTOR_APPOINTED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:arvind-kush","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Arvind Kush seat on Inhibikase Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1tc35xefu9dqa","event_type":"DIRECTOR_APPOINTED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:david-canner-ph-d","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"David Canner, Ph.D. seat on Inhibikase Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1i4q4h218pvifm","event_type":"DIRECTOR_APPOINTED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:roberto-bellini","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Roberto Bellini seat on Inhibikase Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1q9ixsidcaasg","event_type":"COMMITTEE_CREATED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:committee:inhibikase-therapeutics-inc:audit-chair-compensation","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Audit · Chair; Compensation committee of Inhibikase Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:d7dmyqk3iah6","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:arvind-kush","alpha:committee:inhibikase-therapeutics-inc:audit-chair-compensation"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Arvind Kush member of Audit · Chair; Compensation, effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1jje2v8i9fy3w","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:amit-munshi","alpha:committee:inhibikase-therapeutics-inc:compensation"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:20"],"evidence_ids":["alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949"],"summary":"Amit Munshi member of Compensation, effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1f1thr8e53txq","event_type":"COMMITTEE_CREATED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:committee:inhibikase-therapeutics-inc:nominating-and-governance-chair","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Nominating and Governance · Chair committee of Inhibikase Therapeutics, Inc., effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:17cd0151grud3j","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2024-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:roberto-bellini","alpha:committee:inhibikase-therapeutics-inc:nominating-and-governance-chair"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Roberto Bellini member of Nominating and Governance · Chair, effective 2024-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:5bk2hd1tmzbhp","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-16T13:52:50.363049+00:00","subject_ids":["alpha:person:roy-freeman-m-d","alpha:company:53547177-59fc-48ea-9605-a3e44c358510"],"caused_claim_ids":["alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3"],"summary":"Roy Freeman, M.D. seat on Inhibikase Therapeutics, Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:5","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:amit-munshi","object_label":"Amit Munshi","object_source_name_forms":[],"value":"Amit Munshi: Director, Compensation","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:amit-munshi","name":"Amit Munshi"},"title":"Director","role_category":"director","committee":"Compensation","is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2024-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-05-12","effective_from":"2024-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:6","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:arvind-kush","object_label":"Arvind Kush","object_source_name_forms":[],"value":"Arvind Kush: Director, Audit · Chair; Compensation","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:arvind-kush","name":"Arvind Kush"},"title":"Director","role_category":"director","committee":"Audit · Chair; Compensation","is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2024-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-05-12","effective_from":"2024-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:8","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:david-canner-ph-d","object_label":"David Canner, Ph.D.","object_source_name_forms":[],"value":"David Canner, Ph.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:david-canner-ph-d","name":"David Canner, Ph.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2024-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-05-12","effective_from":"2024-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:10","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:mark-iwicki","object_label":"Mark Iwicki","object_source_name_forms":[],"value":"Mark Iwicki: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:mark-iwicki","name":"Mark Iwicki"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2025-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2025-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-05-12","effective_from":"2025-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:11","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:roberto-bellini","object_label":"Roberto Bellini","object_source_name_forms":[],"value":"Roberto Bellini: Director, Nominating and Governance · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:roberto-bellini","name":"Roberto Bellini"},"title":"Director","role_category":"director","committee":"Nominating and Governance · Chair","is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2024-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-05-12","effective_from":"2024-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:12","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:roy-freeman-m-d","object_label":"Roy Freeman, M.D.","object_source_name_forms":[],"value":"Roy Freeman, M.D.: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:roy-freeman-m-d","name":"Roy Freeman, M.D."},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-05-12","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:13","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:vincent-aurentz","object_label":"Vincent Aurentz","object_source_name_forms":[],"value":"Vincent Aurentz: Director, Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:vincent-aurentz","name":"Vincent Aurentz"},"title":"Director","role_category":"director","committee":"Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2025-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2025-01-01","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-05-12","effective_from":"2025-01-01","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:14","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:chris-cabell-m-d","object_label":"Chris Cabell, M.D.","object_source_name_forms":[],"value":"Chris Cabell, M.D.: President and Head of Research and Development","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:chris-cabell-m-d","name":"Chris Cabell, M.D."},"title":"President and Head of Research and Development","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-03-26","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-03-26","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:4677cf46d4312514a369c9980988ca1b826ef2c79f258338999aeefa62c8ce3f","identity_scope":"source_document_reference","source_type":"sec_filing","title":"IKT 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm","source_date":"2026-03-26T00:00:00+00:00","retrieved_at":"2026-05-16T03:52:59.915475+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-03-26T00:00:00+00:00","effective_from":"2026-03-26","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:15","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:david-mcintyre","object_label":"David McIntyre","object_source_name_forms":[],"value":"David McIntyre: Chief Financial Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:david-mcintyre","name":"David McIntyre"},"title":"Chief Financial Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-03-26","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-03-26","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:267fc6e9478bfc77e8e15176a516a660226d070498ea965a58148cae2381f6c9","identity_scope":"source_document_reference","source_type":"sec_filing","title":"IKT 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm","source_date":"2026-03-26T00:00:00+00:00","retrieved_at":"2026-05-16T03:53:00.366466+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-03-26T00:00:00+00:00","effective_from":"2026-03-26","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:leadership_role:16","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:mark-iwicki","object_label":"Mark Iwicki","object_source_name_forms":[],"value":"Mark Iwicki: Chief Executive Officer and Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:mark-iwicki","name":"Mark Iwicki"},"title":"Chief Executive Officer and Director","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-03-26","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-03-26","valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:document:cee5c39c7287118d2ff6c66487225b929867ec0e421959c8e49a65ce773c4dff","identity_scope":"source_document_reference","source_type":"sec_filing","title":"IKT 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm","source_date":"2026-03-26T00:00:00+00:00","retrieved_at":"2026-05-16T03:52:59.513625+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-03-26T00:00:00+00:00","effective_from":"2026-03-26","effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:20","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Compensation: Chair Dr. David Berman; Members Dr. David Berman (Chair); Amit Munshi; Arvind Kush","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Compensation","canonical_type":"compensation","chair":"Dr. David Berman","members":[{"display_name":"Dr. David Berman","person_slug":"dennis-berman","is_chair":true},{"display_name":"Amit Munshi","person_slug":"amit-munshi","is_chair":false},{"display_name":"Arvind Kush","person_slug":"arvind-kush","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:53547177-59fc-48ea-9605-a3e44c358510:committee_record:24","subject_id":"alpha:company:53547177-59fc-48ea-9605-a3e44c358510","predicate":"alpha:hasBoardCommittee","object_id":null,"object_label":null,"object_source_name_forms":[],"value":"Nominating and Governance: Chair Roberto Bellini; Members Roberto Bellini (Chair); Vincent Aurentz","claim_type":"committee_record","predicate_id":"alpha:predicate:committee_record","predicate_version":1,"machine_key":"committee_record","human_label":"Committee Record","governed_predicate":true,"machine_value":{"name":"Nominating and Governance","canonical_type":"nominating_governance","chair":"Roberto Bellini","members":[{"display_name":"Roberto Bellini","person_slug":"roberto-bellini","is_chair":true},{"display_name":"Vincent Aurentz","person_slug":"vincent-aurentz","is_chair":false}],"source_id":"board_seats"},"corroboration_count":1,"source_claim_count":1,"valid_from":null,"valid_to":null,"recorded_at":"2026-10-16T13:52:50.363049+00:00","sources":[{"id":"alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":null,"effective_from":null,"effective_until":null,"observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"source_reported","review_state":"none","confidence":null,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:5e793c92e2327efc4849fd9b23eadbe479f901826a4830937b43ad48b7172cb3","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"Inhibikase Therapeutics, Inc. DEF 14A 2025-05-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":"2025-05-12","retrieved_at":"2026-04-28T23:21:01.149+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:4677cf46d4312514a369c9980988ca1b826ef2c79f258338999aeefa62c8ce3f","identity_scope":"source_document_reference","source_type":"sec_filing","title":"IKT 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm","source_date":"2026-03-26T00:00:00+00:00","retrieved_at":"2026-05-16T03:52:59.915475+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:267fc6e9478bfc77e8e15176a516a660226d070498ea965a58148cae2381f6c9","identity_scope":"source_document_reference","source_type":"sec_filing","title":"IKT 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm","source_date":"2026-03-26T00:00:00+00:00","retrieved_at":"2026-05-16T03:53:00.366466+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:cee5c39c7287118d2ff6c66487225b929867ec0e421959c8e49a65ce773c4dff","identity_scope":"source_document_reference","source_type":"sec_filing","title":"IKT 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm","source_date":"2026-03-26T00:00:00+00:00","retrieved_at":"2026-05-16T03:52:59.513625+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:1180327227d792cc426f14ddc8696eadc2508ba36d8f621e6b4cd3f73aab0949","identity_scope":"representation_reference","source_type":"board_seats","title":"Audit","publisher":"board_seats","url":"https://www.sec.gov/Archives/edgar/data/1750149/000095017025069152/ikt-proxy-def-annual-jun.htm","source_date":null,"retrieved_at":null,"locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.836,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.9,"cross_source_agreement":0.75,"temporal_completeness":0.526},"diagnostics":{"published_claims":26,"factual_claims":26,"claims_with_linked_evidence":26,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":19,"temporal_claims_with_valid_from":10,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-16T13:52:50.363049+00:00","observed_at":"2026-10-16T13:52:50.363049+00:00","reviewed_at":"2026-10-16T13:52:50.363049+00:00","verified_at":"2026-10-16T13:52:50.363049+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":26,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/inhibikase-therapeutics-inc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/inhibikase-therapeutics-inc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}